These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1242358)

  • 1. [Demonstration of the long term action of an oral retard preparation of verapamil in the conscious dog].
    Raschack M
    Arzneimittelforschung; 1975 Aug; 25(8):1275-8. PubMed ID: 1242358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of an oral retard preparation of verapamil and absorption study in the anesthetized dog].
    Mayer D; Raschack M; Kesselring K
    Arzneimittelforschung; 1975 Aug; 25(8):1272-5. PubMed ID: 241362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacodynamics of orally taken verapamil and verapamil retard as judged by their negative dromotropic effects.
    Schlepper M; Thormann J; Schwarz F
    Arzneimittelforschung; 1975 Sep; 25(9):1452-5. PubMed ID: 1103896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A new approach to the evaluation of the effectiveness of antihypertensive therapy in patients with mild and moderate arterial hypertension based on the example of isoptin retard].
    Arabidze GG; Dmitriev VV; Rogoza AN
    Klin Med (Mosk); 1994; 72(5):27-30. PubMed ID: 7853810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Controlled study on the treatment of hypertension with verapamil in retard form].
    Belz GG; Spies G
    Z Kardiol; 1985 Aug; 74(8):453-9. PubMed ID: 3901562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bioequivalence of generic drugs and substitution: example of depot verapamil].
    Rietbrock N; Fischer A; Menke G
    Z Kardiol; 1987 Oct; 76(10):621-5. PubMed ID: 3318196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration.
    Asthana OP; Woodcock BG; Wenchel M; Frömming KH; Schwabe L; Rietbrock N
    Arzneimittelforschung; 1984; 34(4):498-502. PubMed ID: 6540109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension.
    Frishman WH; Eisen G; Charlap S; Strom JA
    J Clin Hypertens; 1987 Dec; 3(4):605-9. PubMed ID: 3134517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verapamil administration for acute termination of supraventricular tachycardia in dogs.
    Kittleson M; Keene B; Pion P; Woodfield J
    J Am Vet Med Assoc; 1988 Dec; 193(12):1525-9. PubMed ID: 3215811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Isoptin-Retard 240 mg in the treatment of mild and moderate arterial hypertension].
    Arabidze GG; Rogoza AN; Dmitriev VV; Metelitsa TV; Domba GIu; Sitina VK
    Ter Arkh; 1993; 65(9):50-2. PubMed ID: 8303597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Swelling studies and in vitro release of verapamil from calcium alginate and calcium alginate-chitosan beads.
    Pasparakis G; Bouropoulos N
    Int J Pharm; 2006 Oct; 323(1-2):34-42. PubMed ID: 16828245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of food on the bioavailability of a sustained-release verapamil preparation.
    Conway EL; Phillips PA; Drummer OH; Louis WJ
    J Pharm Sci; 1990 Mar; 79(3):228-31. PubMed ID: 2338632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The antiarrhythmic action mechanism of verapamil (Isoptin)].
    Bass O; Friedemann M
    Schweiz Med Wochenschr; 1971 May; 101(21):792-9. PubMed ID: 5143469
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum concentration and antihypertensive effect of slow-release verapamil.
    Schütz E; Ha HR; Bühler FR; Follath F
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S346-9. PubMed ID: 6184566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Isoptin Retard. Pharmacokinetics and pharmacodynamics in patients with angina pectoris].
    Jespersen CM
    Ugeskr Laeger; 1990 May; 152(21):1516-8. PubMed ID: 2193448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of verapamil and nitroglycerin on coronary and systemic hemodynamics in conscious dogs.
    Adachi H; Tomoike H; Nishijima H; Hayashi Y; Yamada A; Nakamura M
    J Pharmacol Exp Ther; 1987 Jun; 241(3):1072-8. PubMed ID: 3110406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination therapy with isosorbide dinitrate and verapamil in patients with coronary heart disease and hypertension: effect on blood pressure, ischemia and left ventricular function].
    Vogler AC; Silber S; Vogel M; Theisen K
    Z Kardiol; 1989; 78 Suppl 2():183-7; discussion 188-9. PubMed ID: 2588761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)].
    Knapp W; Lechleitner P
    Arzneimittelforschung; 1981; 31(9):1482-6. PubMed ID: 7197960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bioequivalence of non-retard verapamil. Realization of a draft monograph exemplified by Veramex 80].
    Gierend M; Baarsma JP; Floris WW
    Med Klin (Munich); 1990 Mar; 85(3):132-40. PubMed ID: 2186259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nicotinic acid blood levels after application of xanthinolnicotinate in a new galenic retard preparation].
    Brenner G
    Arzneimittelforschung; 1975 Feb; 25(2):237-40. PubMed ID: 1173039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.